NEW YORK (GenomeWeb News) – Sequenom officials on Thursday elaborated on the firm's plans to develop a lower-cost noninvasive prenatal test for fetal aneuploidy.

The new test will be targeted toward the international and low-risk markets and will run on a different platform than its MaterniT21 Plus test, which is targeted at high-risk pregnancies and runs on Illumina's HiSeq 2000 sequencer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.